My list of expected/hoped for 2025 Milestones second half 25FY:
New European MDR approval by Feb
Completion of percutaneous Pancosil trial by February and announcement of outcomes by March/April
TGA (re)submission by April
Start enrolment into GBA trial by June
First commercial sales in Germany and UK by June
Completion of enrolment for TRIPP by June.
On target for AUD$1million sales 25FY after release 3 rd quarter results in May
Commissioning of Sydney plant by June
If these happen by June 30 then the share price should be above the 0.9 cent trigger for options uptake.
If all exercised or underwritten, company raises 17 million.
Ann: First Patient in Australia Randomised in TRIPP-FFX Trial, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.010(1.06%) |
Mkt cap ! $13.51M | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | $1.02 | 94.0¢ | $110.7K | 114.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15628 | 95.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 1909 | 2 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |